Compare WATT & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WATT | RLYB |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.1M | 89.2M |
| IPO Year | 2014 | 2021 |
| Metric | WATT | RLYB |
|---|---|---|
| Price | $11.22 | $16.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 138.9K | 6.3K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 6.16 |
| Revenue | ★ $1,154,009.00 | $858,000.00 |
| Revenue This Year | $167.69 | N/A |
| Revenue Next Year | $148.82 | N/A |
| P/E Ratio | ★ N/A | $2.76 |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $3.62 | $0.49 |
| 52 Week High | $36.98 | $17.57 |
| Indicator | WATT | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 51.04 |
| Support Level | $10.17 | $16.50 |
| Resistance Level | $12.19 | $17.30 |
| Average True Range (ATR) | 0.81 | 0.35 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 5.88 | 57.97 |
Energous Corp has developed scalable, over-the-air Wireless Power Network (WPN) technology that integrates semiconductor chipsets, software controls, hardware designs, and antenna systems to enable radio frequency (RF)-based charging for ambient Internet of Things (ambient IoT) devices, transforming supply chain capabilities from limited tracking to overall business intelligence. The WPN technology consists of transmitter systems, receiver integrated circuits, and supporting software designed to deliver power and data to battery-free IoT devices across a range of operating distances and power levels. Its applications include retail sensors, electronic shelf labels (ESLs), asset trackers, air quality monitors, motion detectors, and other monitoring solutions.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.